Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: March 29, 2023

Patent: 8,563,269

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 8,563,269
Title:Modified antibody compositions, methods of making and using thereof
Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
Inventor(s): Stagliano; Nancy E. (Santa Barbara, CA), West; James W. (Santa Barbara, CA), Kamath; Kathryn (Santa Barbara, CA), Bessette; Paul H. (Camarillo, CA), Gluck; Frederick W. (Santa Barbara, CA), Sagert; Jason (Santa Barbara, CA), Daugherty; Patrick (Santa Barbara, CA)
Assignee: CytomX Therapeutics, Inc. (South San Francisco, CA)
Application Number:13/315,623
Patent Claims:see list of patent claims

Details for Patent 8,563,269

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Microbix Biosystems Inc. KINLYTIC urokinase For Injection 021846 01/16/1978 See Plans and Pricing 2029-01-12
Eli Lilly And Company ERBITUX cetuximab Injection 125084 02/12/2004 See Plans and Pricing 2029-01-12
Eli Lilly And Company ERBITUX cetuximab Injection 125084 03/28/2007 See Plans and Pricing 2029-01-12
Amgen, Inc. VECTIBIX panitumumab Injection 125147 09/27/2006 See Plans and Pricing 2029-01-12
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.